23.83 USD
+0.68 (+2.94%)
23.74 USD
-0.09 (-0.38%)
We assign a fundamental rating of 3 out of 10 to SRPT. SRPT was compared to 530 industry peers in the Biotechnology industry. Both the profitability and financial health of SRPT have multiple concerns. SRPT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SRPT has reported negative net income.
SRPT had a negative operating cash flow in the past year.
SRPT had negative earnings in 4 of the past 5 years.
SRPT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
SRPT has a Return On Assets of -7.77%. This is amongst the best in the industry. SRPT outperforms 85.28% of its industry peers.
With an excellent Return On Equity value of -20.57%, SRPT belongs to the best of the industry, outperforming 83.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| ROIC | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 76.25%, SRPT belongs to the best of the industry, outperforming 84.15% of the companies in the same industry.
SRPT's Gross Margin has been stable in the last couple of years.
SRPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
2. Health
2.1 Basic Checks
SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
SRPT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SRPT has more shares outstanding
The debt/assets ratio for SRPT has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.04, we must say that SRPT is in the distress zone and has some risk of bankruptcy.
SRPT has a better Altman-Z score (0.04) than 60.57% of its industry peers.
SRPT has a Debt/Equity ratio of 0.78. This is a neutral value indicating SRPT is somewhat dependend on debt financing.
SRPT's Debt to Equity ratio of 0.78 is on the low side compared to the rest of the industry. SRPT is outperformed by 72.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.04 |
ROIC/WACCN/A
WACC7.5%
2.3 Liquidity
SRPT has a Current Ratio of 2.95. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
SRPT's Current ratio of 2.95 is on the low side compared to the rest of the industry. SRPT is outperformed by 64.91% of its industry peers.
A Quick Ratio of 1.79 indicates that SRPT should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.79, SRPT is doing worse than 76.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.95 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
The earnings per share for SRPT have decreased strongly by -197.60% in the last year.
Looking at the last year, SRPT shows a very strong growth in Revenue. The Revenue has grown by 47.15%.
The Revenue has been growing by 37.94% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
3.2 Future
The Earnings Per Share is expected to grow by 2.74% on average over the next years.
SRPT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.76% yearly.
EPS Next Y-338%
EPS Next 2Y1.49%
EPS Next 3Y-6.52%
EPS Next 5Y2.74%
Revenue Next Year13.31%
Revenue Next 2Y-8.22%
Revenue Next 3Y-7.29%
Revenue Next 5Y-5.76%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SRPT. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 10.15 indicates a reasonable valuation of SRPT.
Based on the Price/Forward Earnings ratio, SRPT is valued cheaper than 98.68% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.88, SRPT is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.15 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SRPT's earnings are expected to decrease with -6.52% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.49%
EPS Next 3Y-6.52%
5. Dividend
5.1 Amount
SRPT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
23.83
+0.68 (+2.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners84.9%
Inst Owner Change0%
Ins Owners5.13%
Ins Owner Change19.41%
Market Cap2.50B
Revenue(TTM)2.41B
Net Income(TTM)-271.51M
Analysts68.24
Price Target30.15 (26.52%)
Short Float %20.17%
Short Ratio4.55
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)122.82%
Min EPS beat(2)98.8%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)-38.28%
Min EPS beat(4)-376.26%
Max EPS beat(4)146.84%
EPS beat(8)6
Avg EPS beat(8)621.83%
EPS beat(12)9
Avg EPS beat(12)401.46%
EPS beat(16)10
Avg EPS beat(16)286.26%
Revenue beat(2)2
Avg Revenue beat(2)14.32%
Min Revenue beat(2)13.04%
Max Revenue beat(2)15.59%
Revenue beat(4)4
Avg Revenue beat(4)9.59%
Min Revenue beat(4)2.86%
Max Revenue beat(4)15.59%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)10
Avg Revenue beat(12)5.55%
Revenue beat(16)12
Avg Revenue beat(16)4.13%
PT rev (1m)-5.86%
PT rev (3m)-8.43%
EPS NQ rev (1m)9.23%
EPS NQ rev (3m)-33.14%
EPS NY rev (1m)-0.26%
EPS NY rev (3m)-20.97%
Revenue NQ rev (1m)0.4%
Revenue NQ rev (3m)9.5%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)3.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.15 | ||
| P/S | 1.03 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.89 | ||
| P/tB | 1.94 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.22
EYN/A
EPS(NY)2.35
Fwd EY9.86%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS23.03
BVpS12.6
TBVpS12.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.25% | ||
| FCFM | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score3
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 290.01% | ||
| Cap/Sales | 5.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.95 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | 0.04 |
F-Score3
WACC7.5%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
EPS Next Y-338%
EPS Next 2Y1.49%
EPS Next 3Y-6.52%
EPS Next 5Y2.74%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
Revenue Next Year13.31%
Revenue Next 2Y-8.22%
Revenue Next 3Y-7.29%
Revenue Next 5Y-5.76%
EBIT growth 1Y-206.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-278.15%
EBIT Next 3Y9.2%
EBIT Next 5Y11.92%
FCF growth 1Y36.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.58%
OCF growth 3YN/A
OCF growth 5YN/A
SAREPTA THERAPEUTICS INC / SRPT FAQ
What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SRPT.
Can you provide the valuation status for SAREPTA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 2 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Overvalued.
What is the profitability of SRPT stock?
SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 3 / 10.
How financially healthy is SAREPTA THERAPEUTICS INC?
The financial health rating of SAREPTA THERAPEUTICS INC (SRPT) is 3 / 10.